Feasibility of Hippocampal Avoidance Radiotherapy for Glioblastoma

Area of Science:

• Radiation oncology
• Neuro-oncology
• Medical physics

Background:

• Glioblastoma (GBM) survival rates are improving for select patient groups.
• Long-term survivors may experience significant neurocognitive dysfunction.
• Hippocampal radiation dose is a potential factor in cognitive decline.

Purpose of the Study:

• To quantify hippocampal radiation doses in glioblastoma patients undergoing radical chemoradiotherapy.
• To compare these doses with those clinically correlated with neurocognitive dysfunction.
• To evaluate the feasibility of reducing hippocampal dose using helical TomoTherapy.

Main Methods:

• Retrospective planning study design.
• Analysis of radiation doses delivered to the hippocampus.
• Comparison with established dose-response data for neurocognitive effects.
• Simulation of dose reduction using helical TomoTherapy planning data.

Main Results:

• Hippocampal radiation doses were quantified in the studied glioblastoma cohort.
• The study identified a correlation between specific radiation doses and neurocognitive dysfunction.
• Helical TomoTherapy demonstrated potential for clinically meaningful hippocampal dose reduction.

Conclusions:

• Improving glioblastoma survival necessitates addressing treatment-related toxicities like neurocognitive dysfunction.
• Hippocampal dose reduction is a viable strategy to preserve cognitive function in long-term survivors.
• Helical TomoTherapy offers a promising approach for minimizing radiation exposure to the hippocampus in glioblastoma patients.